Logo

Daiichi Sankyo Expands its Collaboration with Esperion to Additional Territories

Share this

Daiichi Sankyo Expands its Collaboration with Esperion to Additional Territories

Shots:

  • Esperion to receive $30M up front- ~$175M as sales milestones along with royalties from 5-20% on sales in the territory. Daiichi Sankyo will get exclusive commercialization rights to bempedoic acid and bempedoic acid/ezetimibe combination tablet in S. Korea- Taiwan- Hong Kong- Thailand- Vietnam- Brazil- Macao- Cambodia- and Myanmar
  • The agreement allows for the expansion across geographies in Asia- the Middle East and Latin America. While Daiichi Sankyo holds commercialization rights in these territories- the rights for development and regulatory activities will remain with Esperion
  • With this deal- combined milestones from the Daiichi Sankyo now total over $1.1B

  Ref: Globe Newswire | Image: BioSpace

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions